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Abstract
Introduction During cardiac surgery with cardiopulmonary
bypass (CPB) haemodilution occurs. Hepatic dysfunction after
CPB is a rare, but serious, complication. Clinical data have
validated the plasma-disappearance rate of indocyanine green
(PDR ICG) as a marker of hepatic function and perfusion.
Primary objective of this analysis was to investigate the impact
of haemodilutional anaemia on hepatic function and perfusion by
the time course of PDR ICG and liver enzymes in elective CABG
surgery. Secondary objective was to define predictors of
prolonged ICU treatment like decreased PDR ICG after surgery.
Methods 60 Patients were subjected to normothermic CPB
with predefined levels of haemodilution anaemia (haemotacrit
(Hct) of 25% versus 20% during CPB). Hepatic function and
perfusion was assessed by PDR ICG, plasma levels of aspartate
aminotransferase (ASAT) and α-GST. Prolonged ICU treatment
was defined as treatment ≥ 48 hours.
Results Logistic regression analysis showed that all
postoperative measurements of PDR ICG (P < 0.01), and the
late postoperative ASAT (P  < 0.01) measurement were
independent risk factors for prolonged ICU treatment. The
predictive capacity for prolonged ICU treatment was best of the
PDR ICG one hour after admission to the ICU. Furthermore, the
time course of PDR ICG as well as ASAT and α-GST did not
differ between groups of haemodilutional anaemia.
Conclusions Our study provides evidence that impaired PDR
ICG as a marker of hepatic dysfunction and hypoperfusion may
be a valid marker of prolonged ICU treatment. Additionally this
study provides evidence that haemodilutional anaemia to a Hct
of 20% does not impair hepatic function and perfusion.
Trial registration [ISRCTN35655335]
Introduction
Haemodilution always occurs during cardiac surgery with car-
diopulmonary bypass (CPB). Haemodilution reduces blood
viscosity and vascular resistance, and may increase large ves-
sel blood flow maintaining whole body oxygen delivery [1]. It
appears that the microcirculation can regulate red cell flow
and concentration over a wide range of haematocrit (Hct) lev-
els. Hepatic hypoperfusion and ischaemia are rare but severe
complications after coronary artery bypass grafting (CABG)
[2]. The incidence of hepatic hypoperfusion leading to surgical
interventions ranged between 0.2% and 2% in previous inves-
tigations [3]. In these patients mortality rises as high as 60%
[3]. Inadequate perfusion and oxygenation of the hepat-
osplachnic system seems to damage the mucosa of the intes-
tine before any other tissue is compromised [4]. There is
growing evidence that even transient hepatic hypoperfusion
can lead to severe postoperative complications and affect out-
come [5]. Immunological cascades resulting in immune
α-GST: α-glutathione S-transferase; ASAT: aspartate aminotransferase; BMI: body mass index; CABG: coronary artery bypass graft; CPB: cardiop-
ulmonary bypass; FiO2: fraction of inspired oxygen; Hct: haematocrit; ICG: indocyanine green; ICU: intensive care unit; pCO2: partial pressure of 
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paralysis, sepsis and death are thought to be responsible for
this negative impact [5-9]. Hepatic hypoperfusion resulting in
a decrease in hepatic oxygen delivery seems to be one of the
key factors of developing multi-organ dysfunction syndrome
[10,11]. Therefore, interest is increasing in monitoring hepatic
perfusion in the context of haemodilution in cardiac surgical
patients. However, detection of hepatic hypoperfusion is chal-
lenging, because there are only a few practicable devices
available to gather bedside information in a short period of
time. This is, however, crucial as hepatic perfusion and oxy-
genation is compromised before any systemic sign of hypop-
erfusion is detected [12]. As standard liver function tests are
neither sensitive nor specific to identify patients at risk, a major
problem is the early recognition of patients with impaired
hepatic function [13]. Therefore, hepatic hypoperfusion and
hepatic dysfunction remain disguised for too long in a consid-
erable number of patients. Correction of regional oxygenation
and perfusion might be of pivotal relevance to reduce endothe-
lial damage and ischaemia-reperfusion episodes and thus
might lower the risk of multi-organ dysfunction syndrome after
CPB.
The recent introduction of a new non-invasive method to
measure indocyanine green (ICG) plasma disappearance rate
(PDR) using pulse densitometry offers an opportunity for the
early diagnosis of hepatic dysfunction. Clinical data has vali-
dated PDR ICG as a marker of hepatic function and perfusion
[14]. Previous studies detected a strong association between
PDR ICG and outcome in critically ill patients [15]. Recent
data from our group showed that in uncomplicated CABG sur-
gery PDR ICG increases after CPB [16]. Persistent low PDR
ICG after surgery might be a hint for impaired hepatic per-
fusion and might influence outcome. Recently, our group
undertook a prospective, randomised and controlled study to
investigate oxygen delivery and consumption and the clinical
outcome of patients who were randomly allocated to one of
two Hct groups (20% or 25%) during normothermic CPB
[17]. We report here data from this study regarding hepatic
function and perfusion.
The primary aim of this analysis was to investigate hepatic
function and perfusion by the time course of the PDR ICG and
conventional liver enzymes in different groups of haemodilu-
tional anaemia during CPB in elective CABG surgery. The sec-
ondary aim was to assess the predictive capacity of these a
priori  chosen parameters for prolonged intensive care unit
(ICU) treatment (≥ 48 hours).
Materials and methods
Patients
After institutional approval by the local ethics committee and
preoperative written informed consent, 60 patients undergo-
ing elective CABG surgery were considered eligible for this
randomised, controlled clinical trial [17]. Randomisation was
performed by a computer-generated random list. One patient
had to be excluded from analysis as the autologous blood
showed multiple clots after CPB and could not be retrans-
fused. Fifty-nine patients, 30 patients in the 25%-Hct group
and 29 patients in the 20%-Hct group, remained for statistical
analysis.
Investigational program
Diagnosis, surgery and length of ICU stay were documented
for each patient. Vital signs, routine laboratory parameter and
complications were recorded on a daily basis. Measurements
of the plasma disappearance rate of ICG were performed
immediately after induction of anaesthesia, on admission to the
ICU, six hours after admission to the ICU and on the first post-
operative day. For each measurement, 0.5 mg/kg body weight
ICG (Pulsion Medical AG, Munich, Germany) was injected into
a central vein. The pulse densitrometric dye decay was ana-
lyzed with a commercially available monitor (LiMON-Pulsion
Medical AG, Munich, Germany). Each measurement was
recorded on a laptop. At the same time points, blood for the
analysis of the aspartate aminotransferase (ASAT) and the α-
glutathione S-transferase (α-GST) was drawn. For determina-
tion of the plasma level of the ASAT and the α-GST 2.7 mL
blood was withdrawn. Blood for ASAT was analysed on a
commercial laboratory analyser (MODULAR®  Analytics
D2400, P800, Roche, Germany). The level of α-GST was ana-
lysed by enzyme immune assay (Biotrin, Herpkit®-Á-GST,
Dublin, Ireland) according to the manufacturer's instructions.
The team treating the patient in the operating theatre and in
the ICU was blinded to the ICG PDR measurements and to
the assignment to a haemodilution group to avoid bias.
Anaesthesia management
After oral premedication with midazolam at 0.1 mg/kg body
weight general anaesthesia was introduced in all patients.
Intravenous induction was performed with etomidate (0.2 mg/
kg) and 5 μg/kg fentanyl, 0.1 mg/kg pancuronium, followed by
a continuous infusion of 5 to 10 μg/kg/h fentanyl, repetition
boluses of 0.1 mg/kg midazolam and 0.03 mg/kg pancuro-
nium before the start of CPB. Anaesthesia was maintained
with 0.6 to 1% of end-tidal volume isoflurane. All patients were
ventilated with an oxygen-air mixture (fraction of inspired oxy-
gen (FiO2) 0.5) to maintain an end-tidal partial pressure of car-
bon dioxide (pCO2) of 35 to 45 mmHg. Before induction of
anaesthesia, haemodynamic monitoring was established with
a radial artery catheter for invasive blood pressure monitoring,
arterial blood gas sampling and haemoglobin determinations.
Heart rate, arterial blood pressure (systolic and diastolic) and
central venous pressure were continuously monitored and
recorded (Solar 8000; Marquette Hellige, Freiburg, Germany).
Arterial oxygen saturation was continuously monitored by
pulse oximetry. FiO2 and end-tidal isoflurane concentration, as
well as end-tidal pCO2, were measured (Solar 8000). Addi-
tional monitoring in all patients included oesophageal temper-
ature and tidal volume measurements. After orotracheal
intubation, a four-lumen central venous catheter (Arrow,Available online http://ccforum.com/content/13/5/R149
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Reading, PA, USA) and an introducer sheath for a thermodilu-
tion pulmonary artery catheter (8.5 Fr; Arrow, Reading, PA,
USA) were inserted routinely into the right internal jugular vein.
Haemodilution and cardiopulmonary bypass 
management
Before institution of CPB isovolaemic haemodilution using a
hydroxyethylstarch solution 130/0,4 (Voluven®, Fresenius-
Kabi, Bad Homburg, Germany) was performed to reduce the
Hct to a level of 5 ± 1% above the target Hct-level of 20 ± 1%
or 25 ± 1%, respectively. For all measurement of Hct and
blood lactate, a blood gas analyser (ABL-700 series, Radiom-
eter, Copenhagen, Denmark) was used. This isovolaemic
haemodilution was targeted to a Hct level of 20% during CPB
in one group of patients and 25% during CPB in the other
group of patients.
After sternotomy aprotinin was applied at a dose of 1.5 × 106
IU (total dose of aprotinin was 50.000 KIU/kg bodyweight
including the priming of the CPB). Prior to CPB, 400 U/kg
heparin (Liquemin® Hoffmann-La-Roche, Grenzach-Wyhlen,
Switzerland) and additional boluses of 50 U/kg were given if
necessary to maintain an activated clotting time of at least 480
seconds. Routine CPB priming included HES 10%, balanced
electrolyte solution and heparin (8000 U). CPB was per-
formed under normothermic conditions (blood temperature >
35.0°C) using a membrane oxygenator and centrifugal pump
flows adjusted to the calculated cardiac index of 2.5 l/min/m2.
Warm intermittent antegrade blood cardioplegia was used.
Prediction of prolonged ICU treatment
According to routine clinical practice, all patients are generally
transferred from the ICU the day after surgery, if they fulfill the
discharge criteria according to standard operating procedures
of our department. On average, patients are treated in our
department for two days in the ICU [18]. Prolonged ICU treat-
ment was therefore defined as treatment for 48 hours or more.
A priori we chose age, body mass index (BMI), surgery-related
data, group assignment for haemodilutional anaemia and liver
perfusion/function parameters to be tested for the ability to
predict prolonged ICU treatment.
ICU treatment/discharge criteria
Indication for ICU treatment in this study was given in all cases
of organ dysfunction that were potentially life-threatening,
either alone or in combination. This was assumed in the follow-
ing cases: neurological impairment of different origins (delir-
ium, intoxication, metabolic coma, cerebral insults, elevated
intracerebral pressure); respiratory failure with and without
hypoxia; cardiogenic failure (including life-threatening arrhyth-
mias); state of shock; severe sepsis; massive bleeding; acute
renal failure; or other life-threatening organ dysfunctions.
Patients without any of the above mentioned indications for
ICU treatment were transferred within 24 hours postopera-
tively to the intermediate care unit.
Statistical analysis
Due to deviations from the normal distribution, all analyses
were performed non-parametrically. Results were expressed
as median, 25th to 75th percentiles and interquartile ranges.
Mann-Whitney-U-test and Fisher's test were used for inter-
group differences. Dichotomous variables were examined with
the chi-squared test. In case of small samples, larger but
unbalanced groups, data sets containing ties, or sparse data,
tests were carried out in an exact version. We used a univari-
ate logistic regression model (also exact) to identify parame-
ters that were associated with a prolonged ICU treatment
(response: < 48 hours versus ≥ 48 hours). Data with regard to
hepatic function and perfusion with respect to time were ana-
lysed using nonparametric multivariate analysis of variance for
longitudinal data and small sample sizes in a two-factorial
design (1st factor (prolonged ICU treatment: < 48 hours ver-
sus ≥ 48 hours), 2nd factor (time)) [19]. Therefore, we com-
pared all measurements simultaneously on the corresponding
response curves. A P < 0.05 was considered to be significant.
All tests should be understood as constituting exploratory data
analysis, such that no adjustments for multiple testing have
been made. Numerical calculations were carried out with
SPSS for WINDOWS, Release 14.1 (SPSS Inc, Chicago, IL,
USA), LogXact-7 (Cytel Software Corp, Cambridge, MA,
USA) and SAS 8.02 (SAS Institute Inc., Cary, NC, USA).
Results
Prediction of prolonged ICU treatment
Fifty-three patients were transferred from the ICU within 48
hours. The median ICU treatment in these patients was 22 (20
to 24) hours. Six patients underwent a prolonged ICU stay
with a median duration of ICU treatment of 100 (64 to 107)
hours. Causes of the prolonged ICU treatment were severe
systemic inflammatory response syndrome with vasopressor
treatment (n = 3, one patient died later from septic multiple-
organ failure), prolonged mechanical ventilation due to
severely compromised gas exchange (n = 1), cardiac failure (n
= 3) and postoperative symptomatic transitory psychotic syn-
drome (n = 1). Haemodilutional anaemia did not differ
between patients with and without prolonged ICU treatment
(Figure 1b).
Univariate analysis of a priori chosen parameters for prolonged
ICU treatment showed that the group assignment for
haemodilutional anaemia (P = 0.29), age (P = 0.48), BMI (P =
0.47), cardiac index after surgery (p1 h ITS = 0.86; p6 h ITS = 0.46
and p18 h ITS = 0.31) and venous oxygen saturation after sur-
gery (p1 h ITS= 0.43; p6 h ITS = 0.13 and p18 h ITS = 0.21) did not
influence the length of ICU treatment. Only the postoperative
measurements of PDR ICG (p1 h ITS < 0.01; p6 h ITS = 0.04 and
p18 h ITS < 0.01) and ASAT (p1 h ITS = 0.36; p6 h ITS = 0.02 andCritical Care    Vol 13 No 5    Sander et al.
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p18 h ITS = 0.01) were identified to influence the length of ICU
treatment. Results of the logistic regression analysis of these
selected parameters are provided in Table 1.
Multivariate longitudinal analysis showed that PDR of ICG and
ASAT during the whole study period differed significantly
between patients being transferred within 48 hours from ICU
and patients that were treated longer than 48 hours on the ICU
(Figure 2, P < 0.01 for PDR ICG and P < 0.01 for ASAT).
Influence of haemodilutional anaemia
Baseline parameters did not differ between study groups of
haemodilutional anaemia (Table 2). The targeted level of
haemodilutional anaemia was achieved in both study groups
(Figure 1a). PDR of ICG as well as ASAT and α-GST did not
differ between groups of haemodilutional anaemia (Figure 3).
Surgery and ICU-related data are provided in Table 3. There
were no significant differences between both groups of
haemodilutional anaemia. There were also no significant differ-
ences regarding haemodynamics between both groups of
haemodilutional anaemia, except systemic vascular resistance
one hour after admission to the ICU (Table 4). Two patients in
the 25% hct group versus no patient in the 20% hct group
received an intra-aortal balloon pump for weaning from CPB.
This, however, did not reach statistical significance.
Discussion
The most important finding in this study is that the PDR of ICG
was the only predictive parameter of prolonged ICU treatment.
This was shown in a univariate logistic regression model and a
multivariate longitudinal analysis, testing for possible con-
founders. The second major finding of our investigation was
that haemodilutional anaemia during normothermic CPB to a
Hct of 0.20 did not impair hepatic perfusion and function and
had no impact on postoperative duration of ICU treatment.
Severe hepatic hypoperfusion and dysfunction after cardiac
surgery is a rare but often fatal complication. However, mild
hypoperfusion with increased hepatic oxygen extraction rate
and redistribution of the global cardiac output to other organ
systems than the hepatic system has been reported by several
investigators [12,20]. Therefore, it seems quite reasonable to
monitor hepatic perfusion and function during and after car-
diac surgery in the context of haemodilution during normother-
mic CPB, ICG has been proven by several studies to be a valid
marker for liver function and perfusion [21,22]. After intrave-
nous injection, it is bound to plasma proteins and then exclu-
sively eliminated by hepatocytes into the bile. Previous work
has established that the PDR ICG is a valid marker of hepatic
function and perfusion [23-25].
Haemodilution in this study did not significantly influence
haemodynamics, outcome and hepatic function and perfusion
parameters after normothermic CPB. Therefore, even under
normothermic conditions a Hct of 20% during CPB might be
considered safe with regard to functional parameters such as
PDR ICG and structural integrity of the liver quantified by
ASAT and α-GST. The effect of haemodilution on the per-
fusion of the hepatic region has been investigated previously.
It was demonstrated in an animal study that a haemodilution to
a Hct of 0.20 was associated with increased hepatic perfusion
and increased ICG clearance [26,27]. Later this was also
Figure 1
Haemoglobin levels of different patient populations Haemoglobin levels of different patient populations. (a) Haemoglobin levels of different groups of haemodilutional anaemia during the study period. 
red line: 25% hct group, orange line: 20% hct group. (b) Haemoglobin levels of patients with and without prolonged intensive care unit (ICU) treat-
ment. blue line: patients with 48 hours or more ICU treatment, green line: patients with less than 48 hours ICU treatment. CPB = cardiopulmonary 
bypass.Available online http://ccforum.com/content/13/5/R149
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shown after CABG surgery by the authors' group and others
[28]. In our study we found increased levels of ASAT and α-
GST after surgery without any difference between groups of
haemodilutional anaemia. Increased levels of both enzymes
after cardiac surgery have been reported previously [13,20].
Even if haemodilution was not found to be associated with
hepatic perfusion and function abnormalities after CABG sur-
gery with CPB in this study, some patients have been reported
previously by others to developed postoperative hepatic
hypoperfusion and dysfunction quantified by decreased post-
operative PDR ICG during and after CABG surgery [12,29].
Therefore, even independent from haemodilution during nor-
mothermic CPB, hepatic perfusion might be useful to monitor
because it was shown previously that decreased PDR ICG
might be of prognostic relevance in other settings [15,23].
Sakka and colleagues concluded in his retrospective study in
336 critically ill patients that PDR ICG as a marker of hepatic
perfusion and function is a good predictor of survival in criti-
cally ill patients: mortality increased with lower ICG-PDR val-
ues, and nonsurvivors had significantly lower ICG-PDR values
than survivors [15]. Furthermore in a study in 21 critically ill
patients it was concluded that the PDR ICG can identify
reversible hepatic dysfunction in septic shock, suggesting
good prognosis. Either failure to increase the PDR ICG within
120 hours or an extremely low PDR ICG was a poor prognos-
tic sign [30].
In cardiac surgery, increased proinflammatory responses with
an activation of immune cells like macrophages and granulo-
cytes might be involved in postoperative hepatic dysfunction
[31]. Keeping in mind that hepatic dysfunction and hypoper-
fusion was associated with worse outcome in an ICU setting,
it seems convincing that early postoperative hepatic dysfunc-
tion indicated by a decreased ICG PDR might be associated
with prolonged and complicated postoperative ICU treatment.
This is in line with our finding that the PDR ICG on admission
to the ICU was the best predictor of prolonged ICU treatment.
Evaluation of the plasma concentration of the ASAT has
become clinical routine to estimate liver integrity. Cardiac sur-
gery has been shown previously to increase ASAT concentra-
tion in the plasma [13]. Different authors concluded that the
main reason for the increased ASAT liberation from the hepa-
tocytes might be damage by the systemic inflammation proc-
Table 1
Logistic regression of postoperative PDR ICG, ASAT and α-GST
Coeff. Beta Lower 95% CI of Beta Upper 95% CI of Beta P value
1 hour after admission to ICU
PDR ICG
(%/min)
-0.55 -1.04 -0.21  < 0.01
ASAT
(U/μl)
0.02 -0.03 0.06 0.36
α-GST
[U/μl ]
0.02 -0.01 0.04 0.18
6 hours after admission to ICU
PDR ICG
(%/min)
-0.25 -0.55 -0.01 0.04
ASAT
(U/μl)
0.05 0.01 0.09 0.02
α-GST
(U/μl)
0.07 -0.01 0.15 0.07
18 hours after admission to ICU
PDR ICG
(%/min)
-0.31 -0.58 -0.08  < 0.01
ASAT
(U/μl)
0.02 0.01 0.03 0.01
α-GST
(U/μl)
0.33 -0.39 1.03 0.35
α-GST = α-glutathione S-transferase; ASAT = aspartate aminotransferase; CI = confidence interval; ICG = indocyanine green; ICU = intensive 
care unit; PDR = plasma-disappearance rate.Critical Care    Vol 13 No 5    Sander et al.
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Figure 2
PDR ICG, ASAT and α-GST of patients with (green bars) and without (blue bars) prolonged ICU treatment during the study period PDR ICG, ASAT and α-GST of patients with (green bars) and without (blue bars) prolonged ICU treatment during the study period. α-GST = α-glu-
tathione-S-transferase; ASAT = aspartate aminotransferase; PDR ICG = plasma disappearance rate of indocyanine green.Available online http://ccforum.com/content/13/5/R149
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Figure 3
PDR ICG, ASAT and α-GST of the two groups of haemodilutional anaemia during the study period PDR ICG, ASAT and α-GST of the two groups of haemodilutional anaemia during the study period. red bars: haematocrit (Hct) of 25% during car-
diopulmonary bypass (CPB). yellow bars: Hct of 20% during CPB. α-GST = α-glutathione-S-transferase; ASAT = aspartate aminotransferase; PDR 
ICG = plasma disappearance rate of indocyanine green.Critical Care    Vol 13 No 5    Sander et al.
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Table 2
Baseline characteristics
haematocrit 25% haematocrit 20% P value
Median IQR Median IQR
Age
(years)
60 54-69 64 58-68 0.40
Gender
(m - male/f - female)
26/4 29/0
Height
(m)
1.76 1.72-1.80 1.75 1.72-1.79 0.81
Weight
(kg)
90 80-100 90 80-101 0.95
body mass index
(kg/m2)
28.1 26.1-32.6 28.8 26.9-30.3 0.98
preoperative haematocrit
(%)
41.7 40.1-43 42.2 39.3-45.8 0.72
IQR = interquartile range.
Table 3
Intraoperative outcome measures
haematocrit 25% haematocrit 20% P value
Median IQR Median IQR
CI during CPB
(l/m2/min)
3.2 3.0-3.6 3.2 3.0-3.5 0.40
Temperature during CPB
(°C)
35.5 35.0-35.9 35.7 35.4-36.0 0.21
Cumulative norepinephrine-dosage during CPB (mg) 0.06 0.04-0.09 0.05 0.02-0.09 0.41
Urine volume during CPB
(mL)
148 80-250 150 86-177 0.94
duration of anaesthesia
(min)
300 290-320 313 295-338 0.16
duration of surgery
(min)
200 160-220 203 175-243 0.21
CPB time
(min)
74 52-83 71 63-81 0.72
aortic cross clamp time
(min)
45 32-58 44 38-49 0.81
Length of ICU treatment
(hours)
22 20-24 23 21-27 0.29
Length of mechanical ventilation
(hours)
10 8-13 11 10-14 0.10
APACHE II score 14 10-19 16 14-17 0.13
APACHE = Acute Physiology and Chronic Health Evaluation; CI = cardiac index; CPB = cardiopulmonary bypass; Hct = haemotacrit; ICU = 
intensive care unit.
ess after CPB and transient hepatic hypoperfusion [32].
Nonetheless, as seen in our study, increases are seen late and
are not specific for postoperative complications. This was also
reported previously [33]. Another major shortcoming is that
increased levels of liver enzymes can only indicate damage
and are therefore not suitable to serve as an indication of the
patients' regional perfusion. A more sensitive parameter
should indicate hepatic hypoperfusion that could be treated
before damage to the liver occurs.
Clinically, the α-GST is used to assess postoperative liver
damage and liver integrity after liver transplantation [34]. Again
the main reason for the increased α-GST levels in the plasma
is thought to occur due to systemic inflammation after CPBAvailable online http://ccforum.com/content/13/5/R149
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Table 4
Haemodynamic measurements throughout the study period
haematocrit 25% haematocrit 20% P value
Median IQR Median IQR
Before haemodilution
MAP (mm Hg) 70 65-79 67 62-78 0.42
CVP (mm Hg) 12 10-15 12 9-14 0.31
CI (l/min/m2) 2.2 1.9-2.5 2.1 1.9-2.4 0.39
SVR (dyn/s/cm-5) 1045 863-1264 1099 919-1286 0.47
At the end of surgery
MAP (mm Hg) 69 63-87 72 60-80 0.53
CVP (mm Hg) 9 6-12 11 9-14 0.13
CI (l/min/m2) 3.6 3.2-4.2 3.7 3.2-4.1 0.46
SVR (dyn/s/cm-5) 699 536-811 570 497-788 0.41
1 hour after admission to ICU
MAP (mm Hg) 83 74-92 83 71-89 0.58
C V P  ( m m  H g ) 1 08 - 1 31 27 - 1 4 0 . 4 6
CI (l/min/m2) 3.0 2.6-3.4 3.2 2.8-3.7 0.24
SVR (dyn/s/cm-5) 952 792-1160 798 694-952 0.02
6 hours after admission to ICU
MAP (mm Hg) 79 71-85 73 68-82 0.05
C V P  ( m m  H g ) 1 07 - 1 21 18 - 1 3 0 . 7 7
CI (l/min/m2) 3.1 2.6-3.6 3.0 2.6-3.6 0.74
SVR (dyn/s/cm-5) 870 719-1197 811 611-935 0.26
18 hours after admission to ICU
MAP (mm Hg) 81 73-89 75 69-89 0.54
C V P  ( m m  H g ) 95 - 1 398 - 1 1 0 . 6 3
CI (l/min/m2) 3.2 2.8-4.2 3.5 2.9-4.0 0.68
SVR (dyn/s/cm-5) 848 694-1022 754 629-963 0.61
CI = cardiac index; CVP = central venous pressure; ICU = intensive care unit; IQR = interquartile range; MAP = mean arterial pressure; SVR = 
systemic vascular resistance
and transient hepatic hypoperfusion damaging the liver [32].
However, the α-GST, as other standard liver function tests are,
is neither sensitive nor specific in the identification of patients
with impaired hepatic function [13,35]. Therefore, in a number
of patients hepatic hypoperfusion and dysfunction might
remain disguised for too long a time period. Significant eleva-
tions of α-GST or ASAT point to structural damage to the liver.
Yet this is noticed very late after the onset of hepatic hypoper-
fusion. Thus, detection of elevated liver enzymes cannot be
used to prevent damage to the hepatic system - it can only beCritical Care    Vol 13 No 5    Sander et al.
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used to limit damage. In contrast to this, the early determina-
tion of the PDR ICG might help to identify patients being at risk
of hepatic hypoperfusion and dysfunction that could be
treated before structural damage occurs. This would be in
accordance to our finding that compared with other variables,
an early postoperative decreased PDR ICG was predictive for
complicated and prolonged postoperative ICU treatment.
A major limitation of our study is that we cannot provide a
causal relationship between the decreased PDR ICG and the
observed prolonged ICU treatment. However, this should be
done by goal-directed study aiming at improving the PDR ICG
in patients at risk of hepatic hypoperfusion after cardiac sur-
gery. Another limitation is the rather small sample size of
patients with prolonged ICU treatment. Therefore, the impact
of the PDR ICG on outcome should be studied in a group of
patients with higher perioperative risk for complications. In this
study all patients received aprotinin as our standard antifibri-
nolytic therapy at that time. This was performed because the
evidence of the potential deleterious effects of aprotinin was
not published at the time at which this study was performed.
Nevertheless, as all patients were treated with aprotinin this
should not influence our results.
Conclusions
In conclusion this study found evidence that impaired hepatic
function and perfusion quantified by measurements of PDR
ICG was an early marker of prolonged ICU treatment. There-
fore, PDR ICG might serve as an early marker for compro-
mised regional perfusion and goal-directed strategies aimed at
improving the PDR ICG should be undertaken in cardiac sur-
gical patients at risk to determine whether an outcome benefit
exists. Furthermore, our study of patients undergoing different
levels of haemodilutional anaemia investigating hepatic func-
tion and perfusion showed that we could not observe signifi-
cant differences between hepatic function and perfusion
quantified by measurements of PDR ICG, plasma levels of
ASAT and α-GST. Therefore, haemodilution during CPB to
20% might be considered safe with regard to hepatic per-
fusion and function in patients with no pre-existing gastrointes-
tinal diseases.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MS and CvH prepared the manuscript, carried out the meas-
urements, conceived the study and performed the statistical
analysis. KDW prepared the statistical part of the manuscript
and performed the statistical analysis. KB und TS helped with
the drafting of the manuscript. HG helped with the recruitment
of patients. CS drafted the manuscript, helped with the study
design and coordination. All authors read and approved the
final manuscript.
Acknowledgements
The authors appreciate the diligent linguistic revision of this manuscript 
by Mrs. Sirka Sander (Certified and approved translator of the English 
language) and thank their colleagues Mrs. Lisa Adam, Mrs. Anja Heine-
mann and Alexander Döpke (all from the Department of Anaesthesiology 
and Intensive Care Medicine, Charité University Medicine Berlin, Charité 
Campus Mitte, Germany) for helping with the acquisition of the data as 
well as Mrs. Gerda Siebert, Dipl.-Math., Department of Medical Biome-
try, Charité University Medicine Berlin, Germany), for the detailed statis-
tical advice for analyzing the data.
References
1. Gordon RJ, Ravin M, Rawitscher RE, Daicoff GR: Changes in
arterial pressure, viscosity and resistance during cardiopul-
monary bypass.  J Thorac Cardiovasc Surg 1975, 69:552-561.
2. Bach F, Silomon M, Grundmann U, Sturner J, Graeter T, Larsen R:
Splanchnikusperfusion unter Dopexamin bei kardiochirur-
gischen Eingriffen.  Anaesthesist 1999, 48:713-717.
3. Ott MJ, Buchman TG, Baumgartner WA: Postoperative abdomi-
nal complications in cardiopulmonary bypass patients: a case-
controlled study.  Ann Thorac Surg 1995, 59:1210-1213.
4. Dantzker DR: The gastrointestinal tract. The canary of the
body?  JAMA 1993, 270:1247-1248.
5. Meier-Hellmann A, Reinhart K, Bredle DL, Sakka SG: Therapeutic
options for the treatment of impaired gut function.  J Am Soc
Nephrol 2001, 12(Suppl 17):S65-S69.
6. Tamion F, Richard V, Sauger F, Menard JF, Girault C, Richard JC,
Thuillez C, Leroy J, Bonmarchand G: Gastric mucosal acidosis
and cytokine release in patients with septic shock.  Crit Care
Med 2003, 31:2137-2143.
7. Poeze M, Ramsay G, Buurman WA, Greve JW, Dentener M, Takala
J:  Increased hepatosplanchnic inflammation precedes the
development of organ dysfunction after elective high-risk
surgery.  Shock 2002, 17:451-458.
8. Fink MP: Adequacy of gut oxygenation in endotoxemia and
sepsis.  Crit Care Med 1993, 21:S4-S8.
9. Siems W, Kowalewski J, Werner A, Schimke I, Gerber G: Radical
formation in the rat small intestine during and following
ischemia.  Free Radic Res Commun 1989, 7:347-353.
10. Kern H, Schroder T, Kaulfuss M, Martin M, Kox WJ, Spies CD:
Enoximone in contrast to dobutamine improves hepat-
osplanchnic function in fluid-optimized septic shock patients.
Crit Care Med 2001, 29:1519-1525.
11. Lehmann C, Taymoorian K, Wauer H, Krausch D, Birnbaum J, Kox
WJ: Effects of the stable prostacyclin analogue iloprost on the
plasma disappearance rate of indocyanine green in human
septic shock.  Intensive Care Med 2000, 26:1557-1560.
12. Braun JP, Schroeder T, Buehner S, Dohmen P, Moshirzadeh M,
Grosse J, Streit F, Schlaefke A, Armstrong VW, Oellerich M, Lochs
H, Konertz W, Kox WJ, Spies C: Splanchnic oxygen transport,
hepatic function and gastrointestinal barrier after normother-
mic cardiopulmonary bypass.  Acta Anaesthesiol Scand 2004,
48:697-703.
13. Kumle B, Boldt J, Suttner SW, Piper SN, Lehmann A, Blome M:
Influence of prolonged cardiopulmonary bypass times on
splanchnic perfusion and markers of splanchnic organ
function.  Ann Thorac Surg 2003, 75:1558-1564.
14. Birnbaum J, Lehmann C, Taymoorian K, Krausch D, Wauer H,
Grundling M, Spies C, Kox WJ: [The effect of dopexamine and
Key messages
￿  Our study showed that impaired PDR ICG as a marker 
of hepatic function and perfusion may be a valid marker 
of prolonged ICU treatment.
￿  Our study provides evidence that haemodilutional anae-
mia to a Hct of 20% does not impair hepatic function 
and perfusion.Available online http://ccforum.com/content/13/5/R149
Page 11 of 11
(page number not for citation purposes)
iloprost on plasma disappearance rate of indocyanine green in
patients in septic shock].  Anaesthesist 2003, 52:1014-1019.
15. Sakka SG, Reinhart K, Meier-Hellmann A: Prognostic value of the
indocyanine green plasma disappearance rate in critically ill
patients.  Chest 2002, 122:1715-1720.
16. Sander M, Spies CD, Foer A, Syn DY, Grubitzsch H, Von HC:
Peri-operative plasma disappearance rate of indocyanine
green after coronary artery bypass surgery.  Cardiovasc J Afr
2007, 18:375-379.
17. von Heymann C, Sander M, Foer A, Heinemann A, Spiess B, Braun
J, Kramer M, Grosse J, Dohmen P, Dushe S, Halle J, Konertz WF,
Wernecke KD, Spies C: The impact of an hematocrit of 20%
during normothermic cardiopulmonary bypass for elective low
risk coronary artery bypass graft surgery on oxygen delivery
and clinical outcome - a randomized controlled study
[ISRCTN35655335].  Crit Care 2006, 10:R58.
18. Hein OV, Birnbaum J, Wernecke KD, Konertz W, Jain U, Spies C:
Three-year survival after four major post-cardiac operative
complications.  Crit Care Med 2006, 34:2729-2737.
19. Brunner E, Domhof S, Langer F: Non-parametric analysis of longi-
tudinal data in factorial experiments New York: John Wiley & Sons;
2002. 
20. Jakob SM, Ruokonen E, Takala J: Assessment of the adequacy
of systemic and regional perfusion after cardiac surgery.  Br J
Anaesth 2000, 84:571-577.
21. Autschbach R, Falk V, Lange H, Oellerich M, Walther T, Mohr FW,
Dalichau H: Assessment of metabolic liver function and
hepatic blood flow during cardiopulmonary bypass.  Thorac
Cardiovasc Surg 1996, 44:76-80.
22. Uusaro A, Ruokonen E, Takala J: Gastric mucosal pH does not
reflect changes in splanchnic blood flow after cardiac surgery.
Br J Anaesth 1995, 74:149-154.
23. Kimura S, Yoshioka T, Shibuya M, Sakano T, Tanaka R, Matsuyama
S: Indocyanine green elimination rate detects hepatocellular
dysfunction early in septic shock and correlates with survival.
Crit Care Med 2001, 29:1159-1163.
24. Maynard ND, Bihari DJ, Dalton RN, Beale R, Smithies MN, Mason
RC:  Liver function and splanchnic ischemia in critically ill
patients.  Chest 1997, 111:180-187.
25. Sakka S, Meier-Hellmann A: Indocyanin Green for Assessment
of liver function in Critically Ill Patients.  In Yearbook of Intensive
Care and Emergency Medicine 2001 Berlin-Heidelberg-New
York: Springer Verlag; 2001. 
26. Habler O, Kleen M, Hutter J, Podtschaske A, Tiede M, Kemming G,
Corso C, Batra S, Keipert P, Faithfull S, Messmer K: Effects of
hemodilution on splanchnic perfusion and hepatorenal func-
tion. II. Renal perfusion and hepatorenal function.  Eur J Med
Res 1997, 2:419-424.
27. Kleen M, Habler O, Hutter J, Podtschaske A, Tiede M, Kemming G,
Corso C, Batra S, Keipert P, Faithfull S, Messmer K: Effects of
hemodilution on splanchnic perfusion and hepatorenal func-
tion. I. Splanchnic perfusion.  Eur J Med Res 1997, 2:413-418.
28. Mathie RT, Ohri SK, Batten JJ, Peters AM, Keogh BE: Hepatic
blood flow during cardiopulmonary bypass operations: the
effect of temperature and pulsatility.  J Thorac Cardiovasc Surg
1997, 114:292-293.
29. Kramer WG, Romagnoli A: Effect of surgery and cardiopulmo-
nary bypass on indocyanine green pharmacokinetics.  Tex
Heart Inst J 1986, 13:77-82.
30. Kimura S, Yoshioka T, Shibuya M, Sakano T, Tanaka R, Matsuyama
S: Indocyanine green elimination rate detects hepatocellular
dysfunction early in septic shock and correlates with survival.
Crit Care Med 2001, 29:1159-1163.
31. Koo DJ, Chaudry IH, Wang P: Kupffer cells are responsible for
producing inflammatory cytokines and hepatocellular dys-
function during early sepsis.  J Surg Res 1999, 83:151-157.
32. Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED: Endothelial
cell injury in cardiovascular surgery: the systemic inflamma-
tory response.  Ann Thorac Surg 1997, 63:277-284.
33. Olsson R, Hermodsson S, Roberts D, Waldenstrom J: Hepatic
dysfunction after open-heart surgery.  Scand J Thorac Cardio-
vasc Surg 1984, 18:217-222.
34. Chouker A, Martignoni A, Schauer RJ, Dugas M, Schachtner T,
Kaufmann I, Setzer F, Rau HG, Lohe F, Jauch KW, Peter K, Thiel
M:  Alpha-gluthathione S-transferase as an early marker of
hepatic ischemia/reperfusion injury after liver resection.
World J Surg 2005, 29:528-534.
35. McSweeney ME, Garwood S, Levin J, Marino MR, Wang SX,
Kardatzke D, Mangano DT, Wolman RL: Adverse gastrointestinal
complications after cardiopulmonary bypass: can outcome be
predicted from preoperative risk factors?  Anesth Analg 2004,
98:1610-7. table.